Announcements Trials
Browse Landscape

Phase

Phase 2 33Phase 3 10Phase 1/2 8Phase 1 6Phase NA 2Phase 4 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Recruiting 3Completed 3Unknown 2Withdrawn 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, T-Cell, Peripheral 1Lymphoma, Extranodal NK-T-Cell 1

Interventions

Metformin 16Cyclophosphamide 15Drug Therapy 14Dexamethasone 14Cisplatin 14Cytarabine 11Gemcitabine 10Radiotherapy 9Carboplatin 9Vincristine 8Paclitaxel 8Oxaliplatin 8Idarubicin 8Etoposide 8Docetaxel 8ulipristal acetate 7icotinib 7Sodium Chloride 7Methotrexate 7Fluorouracil 7Dexmedetomidine 7entecavir 6Thalidomide 6Surgical Procedures, Operative 6Sorafenib 6Pemetrexed 6Leuprolide 6Granulocyte Colony-Stimulating Factor 6Epirubicin 6Doxorubicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Unknown × Lenalidomide × Clear all
NCT04040491 2020-05-12

PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma

Zhengzhou University

Phase 4 Unknown
100 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT04038411 2019-07-30

PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma

Zhengzhou University

Phase 4 Unknown
50 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡